FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044806323> ?p ?o ?g. }

• W2044806323 endingPage "1017" @default.
• W2044806323 startingPage "1008" @default.
• W2044806323 abstract "Purpose To determine whether the addition of recombinant human erythropoietin (Epo) could improve the outcomes of anemic patients receiving definitive radiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Methods and Materials Eligible patients had SCCHN, with a plan for continuous-course definitive radiotherapy (66–72 Gy) with or without chemotherapy. Patients with Stage III or IV SCCHN were required to undergo concurrent chemoradiotherapy and/or accelerated fractionation radiotherapy. Preradiotherapy hemoglobin was required to be between 9.0 g/dL and 13.5 g/dL (12.5 g/dL for women). Patients randomized to Epo received 40,000 U once weekly, starting 7–10 days before start of radiotherapy. Results A total of 148 patients were enrolled; 141 were evaluable. Median pretreatment hemoglobin was 12.1 g/dL. Hemoglobin levels at 4 weeks rose by an average of 1.66 g/dL in the Epo arm, compared with an average 0.24 g/dL decrease in the control arm (p = 0.0001). Median follow-up was 2.5 years (3.1 years for surviving patients). There was no statistically significant difference in the primary endpoint of local–regional failure (LRF) rate between the treatment arms. The 3-year LRF rate was 36% for control and 44% for Epo (p = 0.56). There were also no significant differences in local–regional progression-free survival (LRPFS), patterns of failure, overall survival, or toxicity. The 3-year LRPFS rate was 52% for control and 47% for Epo. The overall survival rate was 57% and 56%, respectively. Conclusions The addition of Epo to definitive radiotherapy for SCCHN did not improve outcomes. The study was not specifically designed to detect a potential negative association between Epo and tumor progression/survival. To determine whether the addition of recombinant human erythropoietin (Epo) could improve the outcomes of anemic patients receiving definitive radiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Eligible patients had SCCHN, with a plan for continuous-course definitive radiotherapy (66–72 Gy) with or without chemotherapy. Patients with Stage III or IV SCCHN were required to undergo concurrent chemoradiotherapy and/or accelerated fractionation radiotherapy. Preradiotherapy hemoglobin was required to be between 9.0 g/dL and 13.5 g/dL (12.5 g/dL for women). Patients randomized to Epo received 40,000 U once weekly, starting 7–10 days before start of radiotherapy. A total of 148 patients were enrolled; 141 were evaluable. Median pretreatment hemoglobin was 12.1 g/dL. Hemoglobin levels at 4 weeks rose by an average of 1.66 g/dL in the Epo arm, compared with an average 0.24 g/dL decrease in the control arm (p = 0.0001). Median follow-up was 2.5 years (3.1 years for surviving patients). There was no statistically significant difference in the primary endpoint of local–regional failure (LRF) rate between the treatment arms. The 3-year LRF rate was 36% for control and 44% for Epo (p = 0.56). There were also no significant differences in local–regional progression-free survival (LRPFS), patterns of failure, overall survival, or toxicity. The 3-year LRPFS rate was 52% for control and 47% for Epo. The overall survival rate was 57% and 56%, respectively. The addition of Epo to definitive radiotherapy for SCCHN did not improve outcomes. The study was not specifically designed to detect a potential negative association between Epo and tumor progression/survival." @default.
• W2044806323 created "2016-06-24" @default.
• W2044806323 creator A5001104767 @default.
• W2044806323 creator A5030250461 @default.
• W2044806323 creator A5030727782 @default.
• W2044806323 creator A5037043658 @default.
• W2044806323 creator A5037814677 @default.
• W2044806323 creator A5045462759 @default.
• W2044806323 creator A5045794333 @default.
• W2044806323 creator A5066832039 @default.
• W2044806323 creator A5089737672 @default.
• W2044806323 date "2007-11-01" @default.
• W2044806323 modified "2023-10-12" @default.
• W2044806323 title "Radiotherapy With or Without Erythropoietin for Anemic Patients With Head and Neck Cancer: A Randomized Trial of the Radiation Therapy Oncology Group (RTOG 99-03)" @default.
• W2044806323 cites W103389783 @default.
• W2044806323 cites W1567575891 @default.
• W2044806323 cites W1867073577 @default.
• W2044806323 cites W1885881044 @default.
• W2044806323 cites W189180901 @default.
• W2044806323 cites W1931089045 @default.
• W2044806323 cites W1965193139 @default.
• W2044806323 cites W1967262887 @default.
• W2044806323 cites W1970997581 @default.
• W2044806323 cites W1989132762 @default.
• W2044806323 cites W1999594654 @default.
• W2044806323 cites W2002189627 @default.
• W2044806323 cites W2004474968 @default.
• W2044806323 cites W2004967129 @default.
• W2044806323 cites W2014481700 @default.
• W2044806323 cites W2022342238 @default.
• W2044806323 cites W2030100394 @default.
• W2044806323 cites W2034375425 @default.
• W2044806323 cites W2037068261 @default.
• W2044806323 cites W2039725146 @default.
• W2044806323 cites W2054428256 @default.
• W2044806323 cites W2074044281 @default.
• W2044806323 cites W2074308841 @default.
• W2044806323 cites W2082250901 @default.
• W2044806323 cites W2085348371 @default.
• W2044806323 cites W2092143421 @default.
• W2044806323 cites W2098002323 @default.
• W2044806323 cites W2100395142 @default.
• W2044806323 cites W2101697047 @default.
• W2044806323 cites W2114380559 @default.
• W2044806323 cites W2121184390 @default.
• W2044806323 cites W2125373305 @default.
• W2044806323 cites W2126715987 @default.
• W2044806323 cites W2140941208 @default.
• W2044806323 cites W2151415400 @default.
• W2044806323 cites W2156671739 @default.
• W2044806323 cites W2162885883 @default.
• W2044806323 cites W2163066827 @default.
• W2044806323 cites W2164837040 @default.
• W2044806323 cites W2168865951 @default.
• W2044806323 cites W2328544537 @default.
• W2044806323 cites W2353835 @default.
• W2044806323 doi "https://doi.org/10.1016/j.ijrobp.2007.04.063" @default.
• W2044806323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17716826" @default.
• W2044806323 hasPublicationYear "2007" @default.
• W2044806323 type Work @default.
• W2044806323 sameAs 2044806323 @default.
• W2044806323 citedByCount "105" @default.
• W2044806323 countsByYear W20448063232012 @default.
• W2044806323 countsByYear W20448063232013 @default.
• W2044806323 countsByYear W20448063232014 @default.
• W2044806323 countsByYear W20448063232015 @default.
• W2044806323 countsByYear W20448063232016 @default.
• W2044806323 countsByYear W20448063232017 @default.
• W2044806323 countsByYear W20448063232018 @default.
• W2044806323 countsByYear W20448063232020 @default.
• W2044806323 countsByYear W20448063232021 @default.
• W2044806323 countsByYear W20448063232022 @default.
• W2044806323 countsByYear W20448063232023 @default.
• W2044806323 crossrefType "journal-article" @default.
• W2044806323 hasAuthorship W2044806323A5001104767 @default.
• W2044806323 hasAuthorship W2044806323A5030250461 @default.
• W2044806323 hasAuthorship W2044806323A5030727782 @default.
• W2044806323 hasAuthorship W2044806323A5037043658 @default.
• W2044806323 hasAuthorship W2044806323A5037814677 @default.
• W2044806323 hasAuthorship W2044806323A5045462759 @default.
• W2044806323 hasAuthorship W2044806323A5045794333 @default.
• W2044806323 hasAuthorship W2044806323A5066832039 @default.
• W2044806323 hasAuthorship W2044806323A5089737672 @default.
• W2044806323 hasConcept C126322002 @default.
• W2044806323 hasConcept C126894567 @default.
• W2044806323 hasConcept C141071460 @default.
• W2044806323 hasConcept C143998085 @default.
• W2044806323 hasConcept C168563851 @default.
• W2044806323 hasConcept C203092338 @default.
• W2044806323 hasConcept C2776164570 @default.
• W2044806323 hasConcept C2776530083 @default.
• W2044806323 hasConcept C2776694085 @default.
• W2044806323 hasConcept C2778424827 @default.
• W2044806323 hasConcept C2778534260 @default.
• W2044806323 hasConcept C2778917026 @default.
• W2044806323 hasConcept C509974204 @default.
• W2044806323 hasConcept C71924100 @default.
• W2044806323 hasConcept C90924648 @default.

• next